Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Internal documents show Gilead held off on developing new therapies, such as Descovy, a potentially less toxic version of Truvada.
Changes in kidney function were small for those using TDF/FTC either daily or on-demand for HIV prevention.
Over half of people with HIV and 17% of those newly diagnosed are 50 and older.
Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.
While antiretroviral therapy is beneficial for HIV-positive people with reduced kidney function, they should not take Viread (tenofovir).
There is an apparent link between taking Viread (tenofovir) and developing kidney damage among HIV-positive people with low body weight.
An investigational single-tablet combination regimen to treat HIV has comparable efficacy to and is less toxic than a similar regimen of indiv...
Researchers have developed a scoring system to estimate the five-year risk for developing kidney disease among HIV-positive men.
Tenofovir raises the risk of kidney dysfunction among people with HIV, but the adverse effect occurs mostly within the first two years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.